Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis
0 0.5 1 1.5 2+ Severe case 34% Improvement Relative Risk Case 20% c19vitamind.com/israel.html Favors vitamin D Favors control
10 September 2020 - Analysis of outcomes based on serum levels
Vitamin D deficiency is associated with higher risks for SARS-CoV-2 infection and COVID-19 severity: a retrospective case–control study
Israel et al., Internal and Emergency Medicine, doi:10.1007/s11739-021-02902-w (Peer Reviewed)
Source   PDF   Share   Tweet
Retrospective 41,757 PCR+ patients in Israel and 417,570 matched contols, showing an inverse correlation between vitamin D levels and the risks of SARS-CoV-2 infection and of severe disease in those infected. COM-0046–20.
risk of severe case, 33.9% lower, RR 0.66, p < 0.001, high D levels 423 of 1,036 (40.8%) cases, 509 of 934 (54.5%) controls, NNT 7.3, case control OR, >75 nmol/L vs. <30 nmol/L, multivariable.
risk of case, 19.7% lower, RR 0.80, p < 0.001, high D levels 6,152 of 15,892 (38.7%) cases, 73,810 of 159,193 (46.4%) controls, NNT 39, case control OR, >75 nmol/L vs. <30 nmol/L, among COVID+ cases, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes.
Israel et al., 9/10/2020, retrospective, population-based cohort, Israel, Middle East, peer-reviewed, 9 authors, study period 1 March, 2020 - 31 October, 2020.
All Studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit